These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20516522)

  • 1. HIV vaccine development.
    Watkins DI
    Top HIV Med; 2010; 18(2):35-6. PubMed ID: 20516522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.
    Matano T; Kano M; Nakamura H; Takeda A; Nagai Y
    J Virol; 2001 Dec; 75(23):11891-6. PubMed ID: 11689672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
    Michelini Z; Negri DR; Baroncelli S; Catone S; Comini A; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Rovetto C; Liljestrom P; Norley S; Heeney J; Titti F
    J Med Primatol; 2004 Oct; 33(5-6):251-61. PubMed ID: 15525326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
    Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
    Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection.
    Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Pavone-Cossut MR; Macchia I; Farcomeni S; Tenner-Racz K; Racz P; Ensoli B; Titti F
    J Med Primatol; 2007 Aug; 36(4-5):180-94. PubMed ID: 17669207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.
    Allen TM; Mortara L; Mothé BR; Liebl M; Jing P; Calore B; Piekarczyk M; Ruddersdorf R; O'Connor DH; Wang X; Wang C; Allison DB; Altman JD; Sette A; Desrosiers RC; Sutter G; Watkins DI
    J Virol; 2002 Apr; 76(8):4108-12. PubMed ID: 11907251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection.
    Lynch RM; Yamamoto T; McDermott AB
    Curr Opin HIV AIDS; 2013 Jul; 8(4):288-94. PubMed ID: 23666390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.